Finoriq research workspace
bioAffinity Technologies, Inc. (BIAF) SEC Filings & Filing Highlights
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to. Review BIAF SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
- Company
- bioAffinity Technologies, Inc. (BIAF)
- Ticker
- BIAF
- Market Cap
- $3.3M
- Latest Price
- $0.6884
- Industry
- Biotech & Pharma
bioAffinity Technologies, Inc. (BIAF) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for bioAffinity Technologies, Inc. (BIAF).
| Event | Form | Date |
|---|---|---|
| bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momen...bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues | 8-K8.01 | 2026-07-07 |
| Company Newsletter, 1st EditionSee what’s happening at bioAffinity Technologies… | 8-K8.01 | 2026-06-30 |
| bioAffinity Technologies Announces Pricing of $3.2 Million OfferingbioAffinity Technologies Announces Pricing of $3.2 Million Offering | 8-K8.01 | 2026-06-18 |
| The Securities Purchase AgreementOn June 16, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), consummated a best efforts public offering (the “... | 8-K1.01 | 2026-06-18 |
| National Association of Veterans’ Research and Education Foundations to host July 21 webinarbioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Ap... | 8-K8.01 | 2026-06-16 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.